ESR1 and breast carcinoma: To determine whether obese patient sera promotes this nongenomic ERα activity and cross-talk with growth factor signaling pathways, we first examined the contribution of the PI3K/Akt, MAPK, and ERα pathways to obese patient sera-induced breast cancer cell viability and growth.